CompletedPhase 3NCT05180708
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Studying Pachyonychia congenita
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Palvella Therapeutics, Inc.
- Principal Investigator
- Amy Paller, MDNorthwestern University
- Intervention
- QTORIN 3.9% rapamycin anhydrous gel(drug)
- Enrollment
- 87 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (8)
- Stanford University, Palo Alto, California, United States
- Yale University, New Haven, Connecticut, United States
- Park Avenue Dermatology, Orange Park, Florida, United States
- Minnesota Clinical Study Center, Fridley, Minnesota, United States
- Oregon Health and Sciences University, Portland, Oregon, United States
- DermResearch, Inc., Austin, Texas, United States
- University of Utah, Murray, Utah, United States
- Royal London Hospital, London, Whitechapel, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05180708 on ClinicalTrials.govOther trials for Pachyonychia congenita
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05643872A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia CongenitaPalvella Therapeutics, Inc.
- RECRUITINGNCT02321423International Pachyonychia Congenita Research RegistryPachyonychia Congenita Project